Logo image of PYXS

PYXIS ONCOLOGY INC (PYXS) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:PYXS - US7473241013 - Common Stock

1.6707 USD
-1.7 (-50.42%)
Last: 12/18/2025, 10:31:03 AM
Fundamental Rating

2

Overall PYXS gets a fundamental rating of 2 out of 10. We evaluated PYXS against 529 industry peers in the Biotechnology industry. PYXS has a bad profitability rating. Also its financial health evaluation is rather negative. PYXS is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

PYXS had negative earnings in the past year.
In the past year PYXS has reported a negative cash flow from operations.
In the past 5 years PYXS always reported negative net income.
PYXS had a negative operating cash flow in each of the past 5 years.
PYXS Yearly Net Income VS EBIT VS OCF VS FCFPYXS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M -100M

1.2 Ratios

PYXS has a Return On Assets of -78.14%. This is in the lower half of the industry: PYXS underperforms 66.54% of its industry peers.
PYXS's Return On Equity of -109.86% is in line compared to the rest of the industry. PYXS outperforms 43.67% of its industry peers.
Industry RankSector Rank
ROA -78.14%
ROE -109.86%
ROIC N/A
ROA(3y)-49.59%
ROA(5y)-60.34%
ROE(3y)-65.94%
ROE(5y)-86.11%
ROIC(3y)N/A
ROIC(5y)N/A
PYXS Yearly ROA, ROE, ROICPYXS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -50 -100 -150 -200

1.3 Margins

PYXS's Gross Margin of 555.71% is amongst the best of the industry. PYXS outperforms 99.81% of its industry peers.
PYXS does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 555.71%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
PYXS Yearly Profit, Operating, Gross MarginsPYXS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 0 -100 -200 -300 -400

More info and screens

3

2. Health

2.1 Basic Checks

PYXS does not have a ROIC to compare to the WACC, probably because it is not profitable.
PYXS has more shares outstanding than it did 1 year ago.
The number of shares outstanding for PYXS has been increased compared to 5 years ago.
Compared to 1 year ago, PYXS has a worse debt to assets ratio.
PYXS Yearly Shares OutstandingPYXS Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
PYXS Yearly Total Debt VS Total AssetsPYXS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

2.2 Solvency

PYXS has an Altman-Z score of -2.51. This is a bad value and indicates that PYXS is not financially healthy and even has some risk of bankruptcy.
PYXS has a Altman-Z score (-2.51) which is comparable to the rest of the industry.
PYXS has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
PYXS has a Debt to Equity ratio (0.00) which is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -2.51
ROIC/WACCN/A
WACC8.79%
PYXS Yearly LT Debt VS Equity VS FCFPYXS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 100M 200M

2.3 Liquidity

PYXS has a Current Ratio of 5.65. This indicates that PYXS is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of PYXS (5.65) is comparable to the rest of the industry.
PYXS has a Quick Ratio of 5.65. This indicates that PYXS is financially healthy and has no problem in meeting its short term obligations.
PYXS has a better Quick ratio (5.65) than 60.49% of its industry peers.
Industry RankSector Rank
Current Ratio 5.65
Quick Ratio 5.65
PYXS Yearly Current Assets VS Current LiabilitesPYXS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

More info and screens

2

3. Growth

3.1 Past

PYXS shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -21.36%.
EPS 1Y (TTM)-21.36%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to decrease by -3.38% on average over the next years.
Based on estimates for the next years, PYXS will show a very strong growth in Revenue. The Revenue will grow by 31.92% on average per year.
EPS Next Y-42.67%
EPS Next 2Y-15.79%
EPS Next 3Y-14.9%
EPS Next 5Y-3.38%
Revenue Next Year-79.64%
Revenue Next 2Y-41.42%
Revenue Next 3Y-36.29%
Revenue Next 5Y31.92%

3.3 Evolution

PYXS Yearly Revenue VS EstimatesPYXS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2024 2025 2027 2028 2029 2030 2031 2032 100M 200M 300M 400M
PYXS Yearly EPS VS EstimatesPYXS Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 1 -1 -2 -3 -4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for PYXS. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for PYXS. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PYXS Price Earnings VS Forward Price EarningsPYXS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
PYXS Per share dataPYXS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 -1

4.3 Compensation for Growth

PYXS's earnings are expected to decrease with -14.90% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-15.79%
EPS Next 3Y-14.9%

More info and screens

0

5. Dividend

5.1 Amount

PYXS does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

PYXIS ONCOLOGY INC

NASDAQ:PYXS (12/18/2025, 10:31:03 AM)

1.6707

-1.7 (-50.42%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-03 2025-11-03/bmo
Earnings (Next)03-16 2026-03-16/amc
Inst Owners36.9%
Inst Owner Change-2.29%
Ins Owners5.67%
Ins Owner Change0%
Market Cap104.02M
Revenue(TTM)16.15M
Net Income(TTM)-96.29M
Analysts86.67
Price Target7.32 (338.14%)
Short Float %9.71%
Short Ratio5.78
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-0.17%
Min EPS beat(2)-16.71%
Max EPS beat(2)16.37%
EPS beat(4)2
Avg EPS beat(4)3.97%
Min EPS beat(4)-16.71%
Max EPS beat(4)25.73%
EPS beat(8)5
Avg EPS beat(8)15.93%
EPS beat(12)7
Avg EPS beat(12)16.36%
EPS beat(16)7
Avg EPS beat(16)-119.44%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)19.58%
PT rev (3m)19.58%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)-3.81%
EPS NY rev (3m)-1.95%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-0.07%
Revenue NY rev (3m)-1.1%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 36.89
P/FCF N/A
P/OCF N/A
P/B 1.19
P/tB 1.22
EV/EBITDA N/A
EPS(TTM)-1.25
EYN/A
EPS(NY)-1.27
Fwd EYN/A
FCF(TTM)-1.18
FCFYN/A
OCF(TTM)-1.18
OCFYN/A
SpS0.05
BVpS1.41
TBVpS1.37
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -78.14%
ROE -109.86%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 555.71%
FCFM N/A
ROA(3y)-49.59%
ROA(5y)-60.34%
ROE(3y)-65.94%
ROE(5y)-86.11%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.02
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.65
Quick Ratio 5.65
Altman-Z -2.51
F-Score2
WACC8.79%
ROIC/WACCN/A
Cap/Depr(3y)419.47%
Cap/Depr(5y)331.27%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-21.36%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
EPS Next Y-42.67%
EPS Next 2Y-15.79%
EPS Next 3Y-14.9%
EPS Next 5Y-3.38%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year-79.64%
Revenue Next 2Y-41.42%
Revenue Next 3Y-36.29%
Revenue Next 5Y31.92%
EBIT growth 1Y-24.39%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-192.76%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y16.77%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y2.73%
OCF growth 3YN/A
OCF growth 5YN/A

PYXIS ONCOLOGY INC / PYXS FAQ

What is the fundamental rating for PYXS stock?

ChartMill assigns a fundamental rating of 2 / 10 to PYXS.


What is the valuation status for PYXS stock?

ChartMill assigns a valuation rating of 0 / 10 to PYXIS ONCOLOGY INC (PYXS). This can be considered as Overvalued.


Can you provide the profitability details for PYXIS ONCOLOGY INC?

PYXIS ONCOLOGY INC (PYXS) has a profitability rating of 1 / 10.


What is the financial health of PYXIS ONCOLOGY INC (PYXS) stock?

The financial health rating of PYXIS ONCOLOGY INC (PYXS) is 3 / 10.


Can you provide the expected EPS growth for PYXS stock?

The Earnings per Share (EPS) of PYXIS ONCOLOGY INC (PYXS) is expected to decline by -42.67% in the next year.